Background: Cost-effective primary prevention of cardiovascular disease (CVD) in low-and middle-income countries requires accurate risk assessment. Laboratory-based risk tools currently used in high-income countries are relatively expensive and impractical in many settings due to lack of facilities.
Cardiovascular disease (CVD) remains a leading cause of death. However, many countries have seen reductions in age-adjusted death rates over the last 4 decades. Although public health measures such as smoking cessation campaigns and advances in acute care are likely responsible for a large portion of the decline, much of this improvement has been accomplished by identifying individuals at high probability of developing CVD through many identifiable risk factors and implementing targeted interventions to lower risk [1] . Initially, separate guidelines were developed for each individual risk factor and treatment was recommended when the risk factor reached a threshold above a specified level, such as blood pressure >140/90 mm Hg [2] . One limitation, however, is that for any given level of a risk factor, there is a broad range of overall risk for CVD depending on the level of other known risk factors.
In contrast, absolute risk scores using multiple risk factors have better precision and have been adapted into easily used score calculators that are more readily available [3] . Identifying those at highest risk with multiple risk factors will lead to the greatest benefit in terms of delaying onset of disease [4] . In addition, efforts to using a multiple risk factor approach are more cost-effective than basing interventions on single risk factors [5] . The calculation of the absolute CVD risk is usually based on age, sex, tobacco use status, blood pressure levels, and blood cholesterol
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levels as was done with data from the Framingham study and other cohorts [6e10] .
Whereas the absolute risk determination approach holds particular promise for resource scarce settings, blood lipid determinations for screening purposes are far too costly in most developing country settings with limited resources and consequently are unlikely to be adopted as policy in these settings. Therefore, an investigation into the possibility of using other known CVD risk factors that are easier and less costly to measure instead of CVD risk factors that require costly laboratory tests when calculating absolute CVD risk scores has been proposed. This previous work compared the ability to predict first-time fatal and nonfatal CVD events in the NHANES (National Health and Nutrition Examination Survey) I follow-up study cohort by 2 risk prediction models: the laboratory-based Framingham risk score and the Harvard NHANES non-laboratorybased model [11] , which requires only history and physical examination measures and no measure of cholesterol. The exchangeability of the non-laboratory-based score with commonly used laboratory-based approaches has been validated in a U.S. population and assessed for agreement in South Africa [12, 13] , but not in other populations.
Many countries are unlikely in the short term to have their own validated risk score because of the time involved and/or expense of following a cohort with confirmed outcomes for a minimum of 5 to 10 years. As a result, countries have turned to other risk scores such as the laboratory-based risk scores or the non-laboratory-based risk scores such as the Harvard NHANES score [11] or the World Health Organization risk charts [14] based on individual risk factors. In the meantime, countries need to understand whether these risk scores rank individuals comparably even if the absolute risk scores may be overestimated or underestimated. We compare a nonlaboratory-based risk score (Harvard NHANES) with 4 other commonly used laboratory-based risk scores to assess the level of correlations between them in 7 cohorts from 8 different countries representing nearly one-half the world's population.
METHODS
For the primary analysis, we needed to evaluate cohorts that had cross-sectional information to calculate both the non-laboratory-based risk score as well as the laboratory-based risk scores. In a secondary aim, assuming there was a high level of correlation between the non-laboratory-based risk and laboratory-based risk scores, we used the nonlaboratory-based risk score to calculate the absolute CVD risk predicted for a larger set of cohorts where just the nonlaboratory-based risk assessment data was available to estimate the overall risk in these populations representing 10 different countries.
Study population
Data for this study was obtained from 8 institutes that were part of the National, Heart, Lung and Blood Institute (NHLBI)/United Health Group Centers of Excellence (CoE) for chronic disease global network [15] . Each CoE focused on enhancing the monitoring, prevention, and control of chronic diseases by developing their infrastructures for research and training. The studies contributed by the CoE were conducted in both rural and urban populations, and the complete, combined dataset contained records for 64,177 individuals. Each CoE had a primary coordinating site in 1 city but collected data from either multiple locations within 1 country or across multiple countries. In all, a combination of 16 cross-sectional studies, longitudinal cohort studies, randomized trials, and survey studies were conducted in 9 countries and administered by the CoE. For the primary analysis, we evaluated 7 cohorts from 8 countries. The 7 populations include the following: the "Southern Cone" with individuals from Argentina, Chile, and Uruguay; the "Bangalore" group represents a rural Indian population; the "New Delhi and Chennai" group is an urban Indian population; the "Karachi" is an urban Pakistani population coordinated from the New Delhiebased CoE; the "Kenya" population is both rural and urban; the "Peru" group is mixed urban and rural; and the "South Africa" population is from an urban township. More detailed descriptions of some of the populations have been published elsewhere [15e19] . Not all CoE study protocols included the collection of lipid information. Specifically, the "China" population from 120 villages and the "Bangladesh" population did not measure cholesterol values and were not included in the primary analysis. All study protocols were reviewed by the NHLBI and approved by the respective local institutional or ethics review boards. All adults aged 35 to 74 (n ¼ 45,864) with complete risk factor information were eligible for inclusion in these analyses and a dataset containing sociodemographic and anthropometry variables, blood pressure measurements, self-reported medical history, smoking status, and lipid levels was created. All of the risk factor data were obtained using similar standardized methods for collecting selfreported data, anthropometry, and lab assays for lipid level values. Current smokers are defined as people who responded positively to the question, "Which best describes your history of tobacco use? (current, former, never)" except for Peru where current smokers are people who reported daily smoking in response to the question "Do you currently smoke tobacco on a daily basis, or less than daily?" The contents of the original dataset and the data used for the analyses in this paper are described in the Online Appendix (Online Table 1 ).
Risk scores
The primary analyses compared individual-level absolute 10-year CVD risk prediction scores calculated with the non-laboratory-based Harvard NHANES risk score [11] [7] ; and SCORE-Low [7] . Following Gaziano et al. [12] , descriptions of the 5 risk scores, their underlying populations, inputs, and outputs are described in Table 1 [22e26]. Additional score calculation details, including the beta-coefficients, for each score are provided in the Online Appendix (Online Table 2 ). CVD risk scores predict CVD events, which are defined as either fatal or non-fatal myocardial infarction (MI), angina, or ischemic heart disease; peripheral artery disease; coronary artery bypass surgery; percutaneous transluminal coronary angioplasty; transient ischemic attack; congestive heart failure; and fatal or non-fatal cerebrovascular disease.
Statistical procedures
We calculated descriptive statistics of the cohorts within the 8 CoE for age, sex, systolic blood pressure, body mass index, smoking prevalence, diabetes mellitus status, history of hypertension medication use, and total and high-density lipoprotein cholesterol levels. We recognize that many of the populations were not nationally representative by design, but we report the values as illustrative of the range of risk factor prevalences that existed between countries as well as to show what may have driven different predicted CVD risks in the countries. We then compared the correlation between the Harvard NHANES [11] absolute CVD risk scores to individual-level, score-specific rankings of absolute CVD risk for the other 4 laboratory-based scores. Individual-level risk predictions for each of the 5 scores were calculated and then subsequently assigned ranks for each risk score by sex. These ranks were used to assess Spearman rank correlation coefficients between the risk characterizations for the Harvard NHANES score compared with each of the 4 laboratory-based scores for each cohort. Pearson correlation coefficients were not reported because CVD risk prediction values were not normally distributed [27] . Next, individuals were divided into either "high" or "low" risk for each model based on their score-specific rank, and the threshold dividing the 2 risk categories was set to a risk >20% using the 10-year Framingham (2008) CVD risk score as this is a common level of risk used for treatment thresholds in many countries. Using this threshold, we then determined the risk level equivalent equal to the same proportion of individuals using each of the 4 other scores. In other words, if the CVD risk score Tables 1 and 2 . *Representing Argentina, Chile, and Uruguay.
jg SCIENCE identified 15% of the population above this risk threshold, then we used the equivalent risk threshold of the Harvard NHANES score to identify 15% of the population. For example, when comparing the risk scores, a 20% Framingham CVD risk for fatal and nonfatal events is equivalent to a SCORE risk score of approximately 5% for fatal events only. Similar to analyses in a previous publication [12] , the percentage agreement or concordance between Harvard NHANES score and each of the 4 laboratory-based scores was calculated by adding the proportions of individuals who were equivalently characterized as "high" or "low" risk by both scores. We then determined percentage agreement between Harvard NHANES score and the other 4 laboratory-based risk scores by comparing their Spearman rank correlation coefficients. For our secondary aim, we calculated the mean 10-year CVD risk for each cohort using the Harvard NHANES non-laboratory-based score. In order to assess the generalizability of our findings, we standardized each cohort's risk to country-specific age distributions for 2015, as well as to the global age distribution for 2015.
RESULTS
Overall 45,864 persons were included in the overall dataset for analyses of non-laboratory-based risk score calculation. Of these, 19,647 had data available to calculate all 4 laboratory-based risk scores, whereas 35,450 had data available to calculate the Harvard NHANES risk score.
Descriptive statistics
The distribution of risk factors for CVD by CoE is provided in Correlation between ranks of Harvard NHANES risk score and 4 lab-based risk scores. The Spearman rank correlation coefficients for the comparison of the nonlaboratory-based (Harvard NHANES) CVD risk score to the 4 laboratory-based scores are presented in Table 3 . The aggregate Spearman correlation for women was >0.91 for all laboratory-based scores when compared to the nonlaboratory-based score, and the aggregate Spearman correlation for men was >0.92. The correlation between both Using the 20% Framingham risk threshold, we find there is for women and men over 93% agreement and 88% concordance, respectively, in aggregate across the centers between the non-laboratory-based risk score and the 4 laboratory-based risk scores (Table 4 ). The percentage agreement was lowest for the Framingham risk score for men and women. However, all percentage agreement levels were above 80% for all populations. Figures 1A and 1B compare the rank variables for the Harvard NHANES risk score (y-axis), set at a 20% risk score threshold, to the Framingham risk score (x-axis), also using a threshold of 20%. Throughout the figures, we depict the subjects in agreement as either high or low risk based on the threshold in the shaded portions for each risk score. Those in disagreement are unshaded and represent on average of <10% of the population. Given the new risk guidelines used in the United States [21, 28] , we characterized the agreement across the centers between the non-laboratorybased risk score and the 4 laboratory-based risk scores when the ASCVD risk threshold is set at 7.5% (Table 5) . At this threshold, the aggregate level of concordance is 88% for both women and men. We also reproduced additional scatter plots (Figures 2A and 2B) , which compare the rank variables for the Harvard NHANES risk score (y-axis) to the ASCVD risk score (x-axis), for the 7.5% ASCVD risk threshold. In all these graphs, larger ranks indicate higher CVD risk and each risk categorizes individuals as either "high" or "low" risk using the individual risk thresholds as described. These figures show a larger proportion of the population that would be eligible for treatment if this lower threshold is used. However, the percentage agreements were similar for different levels of risk.
The Harvard NHANES risk score was calculated for 35,450 persons for whom the required data were available (Table 6 ). Average non-laboratory-based (Harvard NHANES) 10-year risk was 18.58%, ranging from 12.24% in Bangladesh to 29.32% in China. The China population's risk is higher largely due to the older mean age of the population and its higher mean blood pressure. Figure 3 displays the individual groups' CVD risk scores by age using the Harvard NHANES risk score. As expected, risk scores increased by age in all the cohorts. Risk of CVD was <5% for those under 45-years-old and ranged from 35% to 60% for those ages 74 or older.
DISCUSSION
In this study, we showed that a non-laboratory-based CVD risk score compared with 4 risk scores commonly used throughout the world similarly ranked individuals in all the cohorts studied, which represent 8 different countries. Furthermore, we observed strong agreement in the risk characterization between the laboratory-based risk scores and the non-laboratory-based risk scores. Spearmen correlation was >0.9 for the aggregate of all the cohorts as well as for most of the cohorts for all the risk scores compared. The level of CVD risk characterized in each of the cohorts and between cohorts was quite wide, suggesting the non-laboratory-based risk score performed well across a broad range of at-risk populations. The greatest correlation with Harvard NHANES risk prediction tool was jg SCIENCE with the European SCORE [7] prediction tool with levels of agreement of approximately 95% or higher in most of the cohorts. For any particular country, the percentage correlation was higher for women than for men when comparing the non-laboratory-based score to the SCORE tools, and the correlation was higher for men than for women when comparing the U.S. laboratory-based scores in comparison to the non-laboratory-based risk score. Assessing CVD risk in the general population without the additional costs and inconvenience of measuring cholesterol could be valuable in many low-and middleincome settings. The non-laboratory-based risk score allows health providers to correctly classify those at high versus low risk, which can guide treatment or other intervention decisions that may limit scarce resources to those at highest risk. Furthermore, the ability to make decisions on treatment during a single clinic visit could improve compliance and reduce inefficiencies associated with a required follow-up visit. Many patients have to give up a full day of work to queue in clinic lines, and return visits can discourage further follow-up and engagement and thus could reduce the number of individuals lost to follow-up. In some of the countries, cholesterol testing and the follow-up visit can cost more than $10 per visit [29] . Individuals can now be treated with a year's supply of simvastatin for less than one-half that price [30] . Furthermore, the risk tool can be used by community health workers to assess risk in the community, which can offset demands of busy primary health centers [31] .
Although not all the cohorts evaluated were representative samples, evaluation of all the cohort participants showed that there is significant risk of CVD that exists in many of the populations in the countries evaluated in the analysis. After adjustment to either the country's population structure or the world population, the mean 10-year-CVD risk was about 15%, which is commonly considered as being at "intermediate" risk. Furthermore, after adjustment for age over one-quarter of the population had a risk >20%, which is used by many countries for a threshold for initiating treatment with medications such as statins. If countries begin to adopt lower treatment thresholds such as the United Kingdom (>10%) or the United States (>7.5%) have [28] , then up to 50% of these populations could be considered at high enough risk to warrant intervention. Risks were particularly high in the Chinese group that had higher mean blood pressure and mean age as well as relatively high smoking rates. Even after adjustment to a standard age-distribution, more than 50% of the Chinese had >20% risk using the Framingham equation or the non-laboratory-based risk score. It has been shown that the Framingham risk score overestimates risk in China by as much as 97% [32] , so it is important to acknowledge that the actual risks reported here may be an overestimation. However, our results show that many countries have a significant proportion of their population at risk especially among the elderly. An additional value of the nonlaboratory-based risk score was that in this study w44,000 individuals were able to have their risk score calculated compared with just then w20,000 using the laboratory-based scores. Thus for many countries, in practice as in this research, the potential for access to risk assessment is increased by the non-laboratory-based risk scores.
One limitation of our analysis is that the risk discrimination and performance of the non-laboratory-based risk score has not been validated in these cohorts from these multiple countries. The lack of reliable death data and nonfatal event data in these cross-sectional datasets make it impossible to validate the risk scores. It is possible that any of the risk scores may overestimate or underestimate risk in any of the centers' cohorts. Unfortunately, few of the countries have the cohorts or the linked death and event data to validate risk scores. However, our results show that in the absence of such validations, use of the non-laboratory-based risk score will identify up to 95% of the same people without the millions of dollars required to achieve the laboratory testing. Furthermore, the ability to make treatment or referral decisions on the spot in the community by community health workers could dramatically improve the outcome of those at highest risk without issues of loss to follow-up or inordinate costs.
The risk scores we compared all had different outcomes for the prediction tool. The U.S.-based risk scores used both fatal and non-fatal CVD events as their outcome measures, whereas the European-based SCORE tool used only fatal CVD events. We cannot with certainty say how the different outcomes could affect the results but the highest correlations with the nonlaboratory Harvard NHANES score were with the SCORE risk scores, which use only fatal outcomes. In general, the risk scores based on fatal events only generally produce lower absolute risk scores compared with those calculated using the U.S.-based risk scores. Therefore, a country using a risk score result for initiating therapy may wish to have a higher threshold for those risk scores based on a combination of fatal and non-fatal CVD events.
CONCLUSIONS
A non-laboratory-based risk assessment tool appears to correlate very highly with the most commonly used laboratory-based CVD risk assessment tools in multiple countries across multiple regions of the world. Furthermore, these populations appear to show large portions of the populations at risk for which there are cheap and generically available interventions such as statin and blood pressure treatment. Efforts should begin soon for low-and middle-income countries to increase their screening programs and should include pragmatic screening techniques such as non-laboratory-based multivariate risk tools. jg SCIENCE Values are mean % (95% CI) or %. All missing NHLBI CVD risk scores were excluded from this analysis (n ¼ 35,450). CI, confidence interval(s); NHLBI, National Heart, Lung, and Blood Institute; other abbreviations as in Tables 1 and 2 . *CVD risk is the risk of experiencing CVD over the 10 years following risk assessment using the non-laboratory-based Harvard NHANES score. 46.e1
